BEIJING, May 12, 2025 /PRNewswire/ -- Langjiu, a leading Chinese Baijiu brand of sauce aroma, has been unveiled on Saturday night as one of the most-favored Chinese brands voted by foreigners in the activity "Give a Like for My Favorite China's Brands (2024-2025)". It secured the most votes by foreigners in the baijiu category, highlighting its strong appeal among overseas markets and global consumers.
Co-organized by the Brand Work Office of Xinhua News Agency and China Economic Information Service (CEIS), the global online voting campaign for "Give a Like for My Favorite China's Brands (2024-2025)" has been successfully held for four consecutive years. The annual activity aims to showcase the competitiveness and global influence of Chinese brands, while further enhancing recognition and popularity among foreigners.
Langjiu is produced in Erlang Town, Gulin County, southwest China's Sichuan Province, which is located on the left bank of the Chishui River, one of the world's top ten liquor-producing regions. The company has built the Langjiu Estate in this area, encompassing six ecological brewing zones, spanning 49km along the riverbank. With an annual production capacity of 72,000 tons of premium sauce-aroma baijiu and a storage volume of 265,000 tons, the estate attracts over 200,000 baijiu enthusiasts from around the world each year.
According to the World Brand Summit 2024 report on China's 500 Most Valuable Brands, Langjiu ranked 56th with a brand value of 151.876 billion yuan (around 20.98 billion U.S. dollars), securing a top-three position in the Chinese baijiu industry for 16 consecutive years.
In recent years, Langjiu has expanded its international business footprint to more than 20 countries and regions across the Americas, Europe, Southeast Asia, and East Africa. Through product launches and promotional events, Langjiu has gradually entered into new markets such as Spain, France, Thailand, and Cambodia.
The efforts to take Chinese Baijiu go global boils down to fostering cultural recognition, said Wang Junlin, chairman of Langjiu. The company has long been focusing on quality and culture, continuously enhancing its brand identity.
The year 2025 marks the ninth anniversary of China Brand Day. China's brands are gaining growing recognition in international markets. Langjiu, as a shining business card of Chinese Baijiu brands, will forge ahead with constant effort to promote going global of Chinese culture and cultivating cultural identity at a large scope.
Original link: https://en.imsilkroad.com/p/345552.html
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Xinhua Silk Road: Langjiu voted as most-favored Chinese Baijiu brand by foreigners
Xinhua Silk Road: Langjiu voted as most-favored Chinese Baijiu brand by foreigners
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
